Exidavnemab and lecanemab data presented at the 2025 AD/PD™ congress

Stockholm, April 7, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) presented data on exidavnemab and lecanemab at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™), held in Vienna, Austria, April 1-5. BioArctic’s partner Eisai also presented new data including results from real-world use of lecanemab.

The release as fetched from its publisher. bioarctic.com ↗